2023
Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”
Fesharaki-Zadeh A, Lowe N, Arnsten A. Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19”. Neuroimmunology Reports 2023, 3: 100154. DOI: 10.1016/j.nerep.2022.100154.Peer-Reviewed Original ResearchN-acetylcysteineCognitive deficitsΑ2A-adrenoceptor agonistsPrefrontal cortexCOVID19 infectionPlacebo-controlled trialOpen-label treatmentCommon side effectsExecutive functionPFC connectionsBrain fogAcid blockadeLabel treatmentHypotensive episodesGuanfacine treatmentNMDA receptorsPatient brieflySide effectsClinical experienceGuanfacineCognitive impairmentPatientsPrefrontal connectivityDemonstrate efficacyPrefrontal function
2020
Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?
McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring? Current Opinion In Psychiatry 2020, 34: 177-185. PMID: 33395100, PMCID: PMC7924921, DOI: 10.1097/yco.0000000000000688.Peer-Reviewed Original ResearchConceptsCoronavirus disease 2019Multiple sclerosisParkinson's diseaseNeurodegenerative diseasesAlzheimer's diseaseDisease 2019High riskCOVID-19Heart/lung diseaseHigh-risk comorbid conditionsHospitalized COVID-19 patientsAltered mental statusCOVID-19 patientsMS patientsSuch patientsComorbid conditionsNeurological symptomsPoor outcomeLung diseaseMental statusAdvanced ageSevere diseasePatientsBetter outcomesViral infection